 Sarah Johnson
Concepts (129)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 11 | 2021 | 2756 | 0.970 |
Why?
| | Pancreatic Neoplasms | 3 | 2009 | 225 | 0.840 |
Why?
| | Insulin-Like Growth Factor Binding Protein 5 | 2 | 2009 | 19 | 0.710 |
Why?
| | Adenocarcinoma | 3 | 2007 | 435 | 0.670 |
Why?
| | Gene Expression | 4 | 2018 | 717 | 0.650 |
Why?
| | Gene Expression Profiling | 9 | 2021 | 1119 | 0.640 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2014 | 4 | 0.550 |
Why?
| | Tumor Microenvironment | 1 | 2014 | 145 | 0.500 |
Why?
| | Bone Diseases | 1 | 2014 | 107 | 0.500 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2021 | 895 | 0.490 |
Why?
| | Plasma Cells | 4 | 2021 | 228 | 0.440 |
Why?
| | Evolution, Molecular | 2 | 2021 | 110 | 0.410 |
Why?
| | Kallikreins | 1 | 2007 | 21 | 0.330 |
Why?
| | Neoplasm Proteins | 2 | 2021 | 386 | 0.320 |
Why?
| | Cadherins | 1 | 2007 | 79 | 0.320 |
Why?
| | Bone Marrow | 3 | 2018 | 412 | 0.310 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 303 | 0.300 |
Why?
| | Mutation | 4 | 2021 | 1427 | 0.300 |
Why?
| | Prognosis | 6 | 2021 | 2105 | 0.290 |
Why?
| | Receptors, GABA-A | 1 | 2005 | 17 | 0.290 |
Why?
| | Cell Cycle | 2 | 2021 | 280 | 0.280 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2005 | 28 | 0.280 |
Why?
| | Protein Subunits | 1 | 2005 | 87 | 0.280 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 500 | 0.280 |
Why?
| | Cell Line, Tumor | 4 | 2014 | 1505 | 0.240 |
Why?
| | Disease Progression | 4 | 2021 | 899 | 0.220 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2021 | 50 | 0.220 |
Why?
| | Ubiquitination | 1 | 2021 | 49 | 0.220 |
Why?
| | Lymphoma, B-Cell | 1 | 2021 | 66 | 0.210 |
Why?
| | B-Lymphocytes | 1 | 2021 | 187 | 0.200 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.200 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 198 | 0.200 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 89 | 0.190 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 73 | 0.190 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 15 | 0.180 |
Why?
| | Humans | 18 | 2021 | 52937 | 0.170 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 178 | 0.170 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 2 | 2018 | 79 | 0.170 |
Why?
| | Hematopoietic Stem Cells | 1 | 2019 | 232 | 0.170 |
Why?
| | Character | 1 | 2017 | 3 | 0.170 |
Why?
| | Personality Development | 1 | 2017 | 8 | 0.170 |
Why?
| | Adipocytes | 1 | 2018 | 147 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 597 | 0.160 |
Why?
| | Biopsy | 2 | 2018 | 696 | 0.150 |
Why?
| | Neoplasm, Residual | 1 | 2016 | 176 | 0.140 |
Why?
| | Asymptomatic Diseases | 1 | 2014 | 42 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 716 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2016 | 297 | 0.130 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1143 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2011 | 134 | 0.100 |
Why?
| | Bone and Bones | 1 | 2014 | 519 | 0.100 |
Why?
| | Culture Media, Conditioned | 1 | 2009 | 52 | 0.100 |
Why?
| | Female | 9 | 2021 | 28945 | 0.090 |
Why?
| | Animals | 3 | 2021 | 14792 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2009 | 183 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2009 | 345 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 154 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2021 | 1128 | 0.090 |
Why?
| | Genes, Neoplasm | 1 | 2008 | 37 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2014 | 1699 | 0.090 |
Why?
| | Aged | 5 | 2021 | 10453 | 0.090 |
Why?
| | Mice | 2 | 2021 | 6401 | 0.090 |
Why?
| | Signal Transduction | 2 | 2021 | 1849 | 0.090 |
Why?
| | Male | 8 | 2021 | 28317 | 0.090 |
Why?
| | Microfilament Proteins | 1 | 2006 | 52 | 0.080 |
Why?
| | Calcium-Binding Proteins | 1 | 2006 | 61 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 471 | 0.080 |
Why?
| | Risk Assessment | 1 | 2011 | 1417 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 258 | 0.080 |
Why?
| | Tumor Cells, Cultured | 1 | 2006 | 520 | 0.070 |
Why?
| | Pancreatic Ducts | 1 | 2005 | 15 | 0.070 |
Why?
| | DNA, Complementary | 1 | 2005 | 150 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2006 | 553 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2005 | 178 | 0.070 |
Why?
| | ADP-Ribosylation Factors | 1 | 2003 | 15 | 0.070 |
Why?
| | Middle Aged | 4 | 2021 | 13660 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2005 | 1275 | 0.070 |
Why?
| | Risk Factors | 3 | 2021 | 4005 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2021 | 82 | 0.060 |
Why?
| | Mutation Rate | 1 | 2021 | 41 | 0.050 |
Why?
| | Remission Induction | 1 | 2021 | 223 | 0.050 |
Why?
| | Clone Cells | 1 | 2021 | 87 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 65 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2021 | 146 | 0.050 |
Why?
| | Genes, Tumor Suppressor | 1 | 2021 | 87 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 109 | 0.050 |
Why?
| | Genome, Human | 1 | 2021 | 130 | 0.050 |
Why?
| | Alleles | 1 | 2021 | 281 | 0.050 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 197 | 0.050 |
Why?
| | Recurrence | 1 | 2021 | 698 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2021 | 729 | 0.050 |
Why?
| | Translocation, Genetic | 1 | 2021 | 290 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2021 | 699 | 0.050 |
Why?
| | Adult | 3 | 2021 | 14365 | 0.040 |
Why?
| | Survival Rate | 1 | 2020 | 1015 | 0.040 |
Why?
| | Forecasting | 1 | 2017 | 170 | 0.040 |
Why?
| | Integrins | 1 | 2016 | 39 | 0.040 |
Why?
| | Survival Analysis | 1 | 2018 | 798 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2016 | 129 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2016 | 97 | 0.040 |
Why?
| | Prednisone | 1 | 2016 | 117 | 0.040 |
Why?
| | Transcriptome | 1 | 2018 | 344 | 0.040 |
Why?
| | Models, Genetic | 1 | 2016 | 204 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2018 | 758 | 0.040 |
Why?
| | Melphalan | 1 | 2016 | 178 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2017 | 733 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 402 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 2451 | 0.030 |
Why?
| | Genomics | 1 | 2016 | 268 | 0.030 |
Why?
| | Dexamethasone | 1 | 2016 | 397 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1025 | 0.030 |
Why?
| | Thalidomide | 1 | 2016 | 405 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 3440 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2021 | 3636 | 0.030 |
Why?
| | Phenotype | 1 | 2016 | 842 | 0.030 |
Why?
| | Young Adult | 1 | 2017 | 4306 | 0.020 |
Why?
| | Gene Deletion | 1 | 2008 | 292 | 0.020 |
Why?
| | DNA Damage | 1 | 2008 | 388 | 0.020 |
Why?
| | Adolescent | 1 | 2017 | 6883 | 0.020 |
Why?
| | Substantia Nigra | 1 | 2003 | 13 | 0.020 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2003 | 77 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 2003 | 216 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2003 | 172 | 0.020 |
Why?
| | Base Sequence | 1 | 2003 | 753 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 807 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 1035 | 0.010 |
Why?
| | Myocardium | 1 | 2003 | 468 | 0.010 |
Why?
| | DNA | 1 | 2003 | 576 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 834 | 0.010 |
Why?
|
|
Johnson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|